Malignant pleural mesothelioma remains a highly lethal malignancy despite treatment advances and the advent of multimodal therapy (e.g., surgery, chemotherapy, immunotherapy, radiation therapy). Surgical treatment in addition to systemic chemotherapy is independently associated with improved overall survival in patients with operable malignant pleural mesothelioma; older age, male sex, African-American race, low income, and low educational attainment are associated with poor overall survival in patients with operable disease.[55]Alnajar A, Kareff SA, Razi SS, et al. Disparities in survival due to social determinants of health and access to treatment in US patients with operable malignant pleural mesothelioma. JAMA Netw Open. 2023 Mar 1;6(3):e234261.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802746
http://www.ncbi.nlm.nih.gov/pubmed/36951862?tool=bestpractice.com
1-year relative survival rate (based on 2019 data) for people with mesothelioma in the US (stage at diagnosis):[54]National Cancer Institute Surveillance, Epidemiology, and End Results Program. All cancer sites combined: recent trends in SEER age-adjusted incidence rates, 2000-2020. By sex, delay-adjusted SEER incidence rate, all races/ethnicities, all ages. SEER*Explorer: an interactive website for SEER cancer statistics. Jun 2023 [internet publication].
https://seer.cancer.gov/statistics-network/explorer
5-year relative survival rate (based on 2015 data) for people with mesothelioma in the US (stage at diagnosis):[54]National Cancer Institute Surveillance, Epidemiology, and End Results Program. All cancer sites combined: recent trends in SEER age-adjusted incidence rates, 2000-2020. By sex, delay-adjusted SEER incidence rate, all races/ethnicities, all ages. SEER*Explorer: an interactive website for SEER cancer statistics. Jun 2023 [internet publication].
https://seer.cancer.gov/statistics-network/explorer